Cardiac and metabolic effects in patients who present with a multinodular goitre by Berghout, A. (Arie) et al.
A B S T R A C T
Twenty-six consecutive patients who presented with clinically
euthyroid multinodular goitre were studied for an overnight
fasting serum lipid profile and 24h Holter monitoring. Mean
serum TSH was 0.6 ± 0.4 vs 2.4 ± 1.3 mU/l (p<0.0001)
and mean TT3 2.4 ± 0.4 vs 2.0 ± 0.5 nmol/l (p=0.009)
in patients vs controls (n=15) while mean FT4 was not
different from controls. Total serum HDL, LDL cholesterol
and triglycerides were lower in patients but creatinine,
ferritin and SHBG levels did not differ between patients
and controls. The 24-hour ambulatory continuous ECG
recordings did not demonstrate significant differences in
mean, minimal and maximal heart rate between the study
and the control group. Nocturnal heart rate, measured
between 23.00 and 06.00 hours, also showed no differences
between the two groups. Atrial fibrillation was absent in
both the study and the control group. Premature atrial and
ventricular complexes occurred equally frequently in both
groups. Comparison of patients with a serum TSH below
0.4 mU/l (n=11) and patients with a TSH above 0.4 mU/l
revealed no differences. 
In conclusion, in consecutive patients who present with
multinodular goitre, effects were found on the lipid
profile, but not on the heart. It is argued that in this type
of patients, cardiac effects depend on the degree of sub-
clinical hyperthyroidism. 
I N T R O D U C T I O N
Sporadic nontoxic goitre is one of the most common thyroid
disorders, with a prevalence of 5 to 10% in the general
population.1,2 It is defined as a benign enlargement of the
thyroid, with normal thyroid function in subjects not living
in an endemic area.1 Its aetiology is multifactorial.3 The
natural course of multinodular goitre is characterised by a
gradually increasing size with concomitant rising plasma
thyroid hormone levels and lowering thyroid-stimulating
hormone (TSH) levels.4,5 Ultimately a multinodular goitre
can cause overt hyperthyroidism often complicated by car-
diac rhythm disturbances, in particular atrial fibrillation.6
Recently, in a population-based study, cardiovascular
mortality was found to be increased in elderly people with
a low serum TSH.7 In the last decade, publications
focused on the cardiac effects in patients with a low TSH.
One study published findings of an increased heart rate,
an increased left ventricular mass and impaired diastolic
function in patients on T4 suppressive therapy (‘subclinical
thyrotoxicosis’).8 These findings, however, were not con-
firmed by others.9 Very recently abnormalities in heart
rate and function, similar to the patients with subclinical
thyrotoxicosis due to T4 treatment, were also found in
patients with ‘endogenous’ subclinical hyperthyroidism
i.e. caused by a multinodular goitre or an autonomously
functioning thyroid nodule.10 In the patients of that study
mean values of both T4 and T3 were in the upper normal
range, suggesting an advanced state of subclinical hyper-
thyroidism compared with patients with subclinical
hyperthyroidism in whom only mean serum T3 is
increased. In that study only patients were included with
a low or suppressed TSH level.10 However, in most
multinodular goitre patients plasma TSH levels often vary
between the minimal detection limit of the assay and the
lower normal limit, while plasma T3 and T4 levels are
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still within the normal range. The clinical significance of
these different TSH levels is not known. The aim of this
study was, therefore, to study heart rate, the incidence of
cardiac arrhythmias and metabolic effects in consecutive
patients who presented with clinically euthyroid multi-
nodular goitre. 
S U B J E C T S  A N D  M E T H O D S  
All consecutive patients who presented with clinically
euthyroid multinodular goitre at the medical clinics of
our hospital between June 1997 and October 1999 were
eligible. Those patients taking medication influencing
cardiac or thyroid function, lipid metabolism and/or with
a history of cardiac diseases, hypertension or diabetes
mellitus were excluded. Most complaints were of a
compressive nature or patients wanted to have information
about the nature of the disease. There were no spontaneous
complaints of cardiac palpitations. All patients were
clinically euthyroid and had thyroid hormone levels within
the normal range. A group of 15 healthy females matched
for age served as controls. In all participants an overnight
fasting serum lipid profile and 24h Holter monitoring
were performed.
Assays
Serum TSH was determined using a chemiluminometric
(sandwich) immunoassay, normal range from 0.4 to
4.2 mU/l (interassay variation 4.5-10%). Serum FT4 and
TT3 were determined using a competitive immunoassay,
normal ranges 10.0 to 22.0 pmol/l (interassay variation
4-6.5%) and 1.25 to 2.80 nmol/l (interassay variation 4.5-
7%), respectively. Serum lipids were measured using an
enzymatic colorimetric assay. Plasma creatinine was
measured by a kinetic assay according to Jaffe, and 
ferritin and sex hormone binding globulin (SHBG) by an
immunoluminescent assay.
Electrocardiography 
A standard 12-lead electrocardiogram (ECG) was performed
at the time of inclusion. All ECGs were screened for
frequency, rhythm, conduction and depolarisation
abnormalities and for evidence of left ventricular mass
hypertrophy. A 24-hour ambulatory continuous recording
was performed in each subject at the time of inclusion
for measurement of heart rate and to detect any rhythm
disturbances. 
Statistical analysis
Student’s test was used for comparison of results
between patients and controls. Results are given as the
mean ± standard deviation (SD). All p values are based on
two-tailed analysis.
R E S U L T S
Fifty-eight patients were evaluated. Thirty-two patients were
excluded for single or multiple reasons: cardiac history
(n=10), hypertension (n=8), medication (n=6), diabetes
mellitus (n=4), toxic goitre (n=6), other reasons (n=7).
Twenty-four females and two males were in the patient
group and 15 healthy females served as controls (table 1).
The patients were divided in two subgroups, with a
serum TSH above or below 0.4 mU/l. Mean serum TSH
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Table 1
Characteristics of the multinodular goitre patients (mean ± SD)
PATIENTS PATIENTS ALL PATIENTS CONTROLS P VALUE
TSH >0.4 MU/L TSH <0.4 MU/L
Number 15 11 26 15
Females 14 10 22 15
Mean age (years) 53 ± 10 55 ± 11 54 ± 10 59 ± 10 NS
TSH (mU/l) 0.2 ± 0.2 0.9 ± 0.2 0.6 ± 0.4 2.4 ± 1.3 0.0001
FT4 (pmol/l) 13.4 ± 1.3 14.8 ± 3.0 14.0 ± 2.2 13.7 ± 2.1 NS
TT3 (nmol/l) 2.4 ± 0.4 2.4 ± 0.3 2.4 ± 0.4 2.0 ± 0.5 0.009
Creatinine (mol/l) 58 ± 10 61 ± 9 61 ± 9 64 ± 9 NS
Ferritin (g/l) 52 ± 40 85 ± 45 72 ± 52 116 ± 93 NS
Total cholesterol (mmol/l) 5.3 ± 1.0 5.4 ± 1.0 5.4 ± 1.0 6.2 ± 1.1 0.02
HDL cholesterol (mmol/l) 1.4 ± 0.2 1.3 ± 0.2 1.4 ± 0.3 1.6 ± 0.4 0.02
LDL cholesterol (mmol/l) 3.7 ± 0.9 3.6 ± 0.7 3.7 ± 0.8 4.4 ± 1.1 0.04
Triglycerides (mmol/l) 0.9 ± 0.4 0.8 ± 0.6 0.8 ± 0.5 1.3 ± 0.4 0.009
Sex hormone-binding globulin (nmol/l ) 62.1 ± 32.4 54.1 ± 30.1 61.1 ± 37.7 52.9 ± 28.6 NS
P values: statistic tests between all patients and controls. TT3 = total trijodothyronine, TSH = thyroid-stimulating hormone.
and TT3 levels were lower and higher in both patient
groups compared with the control group, respectively.
Mean serum FT4 levels were not different. Mean total,
HDL and LDL cholesterol and triglyceride levels were
lower in both patient groups. Mean creatinine, ferritin
and SHBG levels did not differ between patients and
controls (table 1).
The 24-hour ambulatory continuous ECG recordings did
not demonstrate differences in mean, minimal and maximal
heart rate between both patient groups and the control
group. Nocturnal heart rate, measured between 23.00 and
06.00 hours also showed no differences between the groups.
Atrial fibrillation was absent in both the patients and the
controls. Premature atrial and ventricular complexes were
observed, but occurred equally frequently in patients and
controls (table 2). Thyroid hormone levels and 24 hour or
nocturnal heart rate were not significantly correlated in
patients and controls.
D I S C U S S I O N  
Reports on effects of ‘endogenous’ subclinical hyper-
thyroidism on heart and lipids are limited. A recent study
showed cardiac abnormalities in patients who were on
TSH suppressive T4 therapy but with thyroid hormone
levels within the normal range. These abnormalities were
reflected by a higher mean daytime and nocturnal heart
rate, a higher prevalence of atrial or ventricular arrhythmias,
an increased cardiac mass and diastolic dysfunction.8
These findings could not be confirmed by another group
of investigators in a comparable patient group.9
Interestingly, however, in another study in T4-suppressed
patients, an increased left ventricular mass and reduced
exercise tolerance was found. If, in these patients, T4
dose was lowered to the minimal amount to keep TSH at
0.1 mU/l, echocardiographic and ergometric parameters
normalised.11 Recently, cardiac abnormalities, this time in
patients with subclinical hyperthyroidism due to a
multinodular goitre, were published by Biondi et al.10 The
authors found an increased basal heart rate and also an
abnormal systolic and diastolic function. In the present
study we were unable to find cardiac effects. The two
studies differ, however, in several aspects. Firstly, our study
is a consecutive study whereas Biondi et al. presented
results of a study of patients selected from a larger number
of outpatients with a low TSH. Secondly, the patients in
Biondi’s study were probably more thyrotoxic than our
patients as reflected by the fact that both mean TT3 and
FT4 levels were in the upper normal range10 whereas in our
patients only mean TT3 was higher. Thirdly, the patients in
Biondi’s study – as in most other studies (table 3) – were
significantly younger than our patients. These differences
could very well explain that their patients showed cardiac
effects whereas ours did not. Interestingly, in a consecutive
study of 102 consecutive multinodular goitre patients
performed in the Amsterdam area several years ago, TT3
was also higher but FT4 was not different compared with
50 healthy adults.4 These data confirm again that in the
natural course of multinodular goitre TT3 levels start to rise
first, before FT4 levels rise, with a concomitant decrease
in plasma TSH levels. Also of interest is the finding in
our study that TT3 was in the upper normal range in all
patients studied, both in patients with a TSH level below
as well as above 0.4 mU/l.
Contrary to the findings in our patients with respect to the
heart, there was evidence of an effect on plasma lipids in
that serum levels were significantly lower than in controls.
However, other metabolic parameters such as SHBG,
ferritin or creatinine, known to be affected by thyroid
hormone, were not different. Similar changes in circulating
lipids have been found in another study in subjects with
subclinical hyperthyroidism.12 In that study, FT4 was also
higher compared with controls, but still within normal
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Table 2
Heart rate and incidence of arrhythmias in multinodular goitre patients
PATIENTS PATIENTS ALL PATIENTS CONTROLS P VALUE
TSH >0.4 MU/L TSH <0.4 MU/L
Number 15 11 26 15
Mean heart rate (bpm) 81 ± 8 81 ± 8 81 ± 8 80 ± 9 NS
Minimal heart rate (bpm) 53 ± 7 54 ± 8 53 ± 7 52 ± 6 NS
Maximal heart rate (bpm) 141 ± 14 151 ± 24 145 ± 19 138 ± 23 NS
Mean nocturnal heart rate 69 ± 9 70 ± 9 70 ± 9 67 ± 6 NS
Minimal nocturnal heart rate 55 ± 7 54 ± 8 54 ± 7 53 ± 6 NS
Maximal nocturnal heart rate 107 ± 13 114 ± 23 110 ± 18 105 ± 11 NS
Premature ventricular complexes >100 3 0 3 3 NS
Premature atrial complexes >100 4 3 7 4 NS
Statistical analysis between all patients and controls. TSH = thyroid-stimulating hormone.
limits.12 In a study of 44 patients with clinically euthyroid
goitre plasma levels of bone gla protein and SHBG were
found to be higher compared with controls in those patients
who had a lowered TSH.13 A study of 27 consecutive
multinodular goitre patients reported elevated levels of
serum osteocalcin, which correlated with FT4 levels.14
TSH was lower and FT4 was higher, but still within the
normal range.14
From an analysis of all available studies of patients with
subclinical hyperthyroidism caused by a multinodular
goitre or with thyrotoxicosis caused by T4 suppressive
therapy it is apparent that cardiac effects are seen in both
groups but not in all studies (table 3).8-10,15-17 It remains
debatable whether endogenous subclinical hyperthyroidism
in patients with a goitre and subclinical thyrotoxicosis
due to exogenous T4 therapy are two different entities. In
both situations plasma TSH levels are low or suppressed.
In endogenous subclinical hyperthyroidism first TT3 and
later both TT3 and FT4 are elevated – within the normal
range – while in subclinical thyrotoxicosis due to T4
suppressive treatment only FT4 is elevated.8 In both
situations TSH is suppressed because the pituitary can
respond independently to changes in plasma levels of T4
that enter the thyrotroph and is locally converted to T3,
and to changes in plasma T3 that is directly taken up by
the pituitary.18 It is also evident that one cannot conclude
from these studies whether the human heart is more
sensitive to plasma T3 or T4 levels, in contrast to the liver
that appears to be sensitive mainly to the plasma T3
concentration. The situation in the human heart is largely
unknown. In neonatal rats cardiac uptake was mostly for
T3 but not T4.19 The conversion of T4 into T3 in human
cardiac myocytes has thus far only indirectly been
demonstrated by the finding of the expression of mRNA
of type II deiodinase.20
In summary, in consecutive patients with euthyroid multi-
nodular goitre metabolic effects are found. The expression
of these effects depends upon the degree of increased
thyroid function as occurring in the natural course of
‘nontoxic’ goitre. 
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